Cargando…
Ethnic Pharmacogenomic Differences in the Management of Asian Patients with Metastatic Prostate Cancer
SIMPLE SUMMARY: With the recognition that ethnicity may influence prognosis and outcomes, there are ongoing controversies over how best to treat patients with prostate cancer. This review discusses recent evidence for the impacts of Asian ethnicity on metastatic prostate cancer treatment. ABSTRACT:...
Autores principales: | Poon, Darren M. C., Chan, Kuen, Chan, Tim, Cheung, Foo-Yiu, Lam, Daisy, Lam, Martin, Law, Ka-Suet, Lee, Conrad, Lee, Eric K. C., Leung, Angus, Sze, Henry, Tong, Chi-Chung, Wong, Kenneth C. W., Kwong, Philip |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8773846/ https://www.ncbi.nlm.nih.gov/pubmed/35053569 http://dx.doi.org/10.3390/cancers14020407 |
Ejemplares similares
-
Real-world experience of cabozantinib in Asian patients with advanced renal cell carcinoma following treatment with VEGFR tyrosine kinase inhibitors and/or immune-checkpoint inhibitors
por: Poon, Darren MC, et al.
Publicado: (2023) -
Abiraterone acetate in metastatic castration-resistant prostate cancer – the unanticipated real-world clinical experience
por: Poon, Darren M. C., et al.
Publicado: (2016) -
Differences in clinical outcome between docetaxel and abiraterone acetate as the first-line treatment in chemo-naïve metastatic castration-resistant prostate cancer patients with or without the ineligible clinical factors of the COU-AA-302 study
por: Poon, Darren M.C., et al.
Publicado: (2018) -
Consensus statements on the management of clinically localized prostate cancer from the Hong Kong Urological Association and the Hong Kong Society of Uro‐Oncology
por: Ma, Wai‐Kit, et al.
Publicado: (2019) -
Epidemiology of Legionnaires’ Disease, Hong Kong, China, 2005−2015
por: Leung, Yiu-Hong, et al.
Publicado: (2020)